Pediatrix Medical Group Inc (MD)

Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in NeonatologyJune 3, 2026 4:30 PM
Business Wire Research Was Conducted Utilizing the Proprietary Pediatrix Clinical Data Warehouse Pediatrix® Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today announced the publication of new research on probiotic use and necrotizing enterocolitis (NEC) in preterm infants, addressing pressing questions about one of the most controversial issues in the field of neonatology. The research was conducted by clinicians affiliated with the Pediatrix Center for Research, Education, Quality and Safety in collaboration with the NEC Society, utilizing data from the Pediatrix Clinical Data Warehouse (CDW), one of the largest databases of neonatal outcomes in the world. Data from the Pediatrix CDW has been utilized in more than 250 peer-reviewed publications. Published in the Journal of Perinatology, a large multicenter study of more than 10,000 extremely preterm infants found that rates of NEC, a serious and potentially life-threatening intestinal disease, rose in hospitals that sharply reduced probiotic use after the U.S. Food and Drug Administration’s (FDA) 2023 warning actions and market withdrawal of probiotics commonly used in NICUs. Because of the low incidence of NEC, a large cohort is critical, particularly in a retrospective study of this kind, demonstrating the importance of the Pediatrix CDW, which may be the only database capable of answering research questions like this relatively quickly. The article notes that the findings suggest that the rapid discontinuation of probiotics may have had unintended harmful consequences for this highly vulnerable neonatal population. At the same time, it emphasizes that the study was observational and did not identify which probiotic strains, doses or products might be most effective or safest. The results add to growing evidence that probiotics may help protect preterm infants from NEC, while underscoring the need for prospective clinical trials and clearer regulatory pathways for products intended for this population. “These findings add important real-world evidence to the ongoing discussion about probiotic use in extremely preterm infants,” said Veeral Tolia, M.D., lead author of the study and director, Clinical Data Warehouse Research. “While additional prospective studies are needed to define the safest and most effective approaches, our analysis suggests that abrupt changes in practice may have meaningful consequences for infants with the highest risk for NEC.” The NEC Society, the world’s leading nonprofit dedicated to understanding and preventing NEC, collaborated on the research. This is the first study utilizing the CDW dataset to involve a nonprofit organization dedicated to integrating patient-families in research. “It is essential for clinicians, scientists, regulators and families to collaborate and invest in science and strategies that protect infants from the devastation of NEC,” said Jennifer Canvasser, MSW, fourth author of the study and founder of the NEC Society. “By partnering with Pediatrix CDW research, we can begin to illuminate urgent gaps in science to improve care so all babies can thrive.” Additional study authors include Monica M. Bennett, Ph.D., Darren Handler, Rachel G. Greenberg, M.D., Robert Ursprung, M.D., Kaashif A. Ahmad, M.D., and Ravi Patel, M.D., MSc. About Pediatrix Medical Group Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors. About the NEC Society The NEC Society is the world’s leading nonprofit dedicated to necrotizing enterocolitis (NEC). The NEC Society brings together patient families, clinicians and scientists to advance NEC research, education and advocacy for a world without NEC. View source version on businesswire.com: https://www.businesswire.com/news/home/20260603699917/en/ For media inquiries or more information, please contact Pediatrix Communications at communications@pediatrix.com. Original: Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology

Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026April 20, 2026 6:45 AM
Business Wire
Pediatrix Medical Group, Inc. (NYSE: MD) will host an investor conference call and webcast on Tuesday, May 5, 2026 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2026. A detailed press release will be issued the morning of May 5, 2026 before the securities markets open.


The investor conference call will be webcast and can be accessed at Pediatrix’s website, www.pediatrix.com/investors.


About Pediatrix Medical Group


Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.


Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, its full year 2026 guidance, future impacts of legal, regulatory, political and macroeconomic developments and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the following: the impact of the Company’s practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the effects of economic conditions on the Company’s business; the effects of the Medicare Access and CHIP Reauthorization Act of 2015, the Affordable Care Act, the One Big Beautiful Bill Act and potential additional healthcare reform; the Company’s relationships with government-sponsored or funded healthcare programs and with managed care organizations and commercial health insurance payors; the impact of state budgetary constraints and uncertainty over the future of Medicaid; the impact of surprise billing legislation; the Company’s transition to a hybrid revenue cycle management model; the timing and contribution of future acquisitions or organic growth initiatives; the Company’s ability to comply with the terms of debt financing arrangements; and the effects of the Company’s transformation initiatives, including our renewed focus, and growth strategy for, the Company’s hospital-based and maternal fetal businesses.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260420212740/en/
FOR MORE INFORMATION:

Kasandra Rossi

Executive Vice President, Chief Financial Officer and Treasurer

954-692-7163

kasandra.rossi@pediatrix.com


Original: Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026

Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal MedicineMarch 26, 2026 4:30 PM
Business Wire
Maternal-Fetal Medicine Specialists of Tennessee Provides Vital Care for Greater Nashville Area


Pediatrix® Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today announced its expansion in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, further advancing its commitment to delivering high-quality maternal-fetal care. The practice will continue to serve patients at five locations throughout the Greater Nashville area as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix Medical Group banner.


“We are pleased to welcome Tennessee Maternal-Fetal Medicine to the Pediatrix family,” said Mark Ordan, Chief Executive Officer and Chair of the Board. “This new partnership bolsters our nationally leading maternal-fetal medicine specialty services and ensures that patients in Middle Tennessee have access to exceptional care during pregnancy. Further, this practice has built a national reputation as thought leaders in maternal-fetal medicine, which can now be applied to the nation’s largest footprint in this sector.”


The practice includes four board-certified physicians complemented by six advanced practice providers, offering comprehensive maternal-fetal medicine (MFM) services to expectant mothers across the region. With this addition, Pediatrix strengthens its presence and ability to meet the growing needs of communities in Middle Tennessee.


“We joined Pediatrix in order to have a larger footprint to improve quality and outcomes in MFM care, not just in Tennessee, but throughout the United States,” said Connie Graves, M.D., practice leader and noted researcher.


This expansion highlights Pediatrix’s ongoing commitment to advancing maternal-fetal medicine and improving access to specialized care for families in the Greater Nashville area. The partnership brings together renowned expertise and innovative approaches, helping address critical challenges in maternal health across the region.


This was a cash transaction, and it is expected to be immediately accretive to Pediatrix’s earnings. No additional terms of the transaction were disclosed.


About Pediatrix Medical Group


Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.


Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, whether this transaction will be accretive to the Company’s earnings, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the following: the impact of the Company’s practice portfolio management plans; the effects of economic conditions on the Company’s business; the effects of government regulation and healthcare reform; the Company’s relationships with government-sponsored or funded healthcare programs and with managed care organizations and commercial health insurance payors; the impact of state budgetary constraints and uncertainty over the future of Medicaid; the impact of surprise billing legislation; the Company’s transition to a hybrid revenue cycle management model; the timing and contribution of future acquisitions or organic growth initiatives; the Company’s ability to comply with the terms of debt financing arrangements; and the effects of the Company’s transformation initiatives, including our renewed focus, and growth strategy for, the Company’s hospital-based and maternal fetal businesses.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326894999/en/
For media inquiries or more information, please contact Pediatrix Communications at communications@pediatrix.com.


Original: Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine

Pediatrix Welcomes Two Nationally Renowned Physician LeadersMarch 24, 2026 5:10 PM
Business Wire
Dr. James Barry, who will join as Chief Clinical Quality & Transformation Officer, and Dr. Jochen Profit, who will serve as Chief Quality Advisor, bring extraordinary reputations as care quality experts


Pediatrix® Medical Group, Inc. (NYSE: MD), a leading provider of physician services, is pleased to announce that James Barry, M.D., MBA, will soon join the organization as Chief Clinical Quality & Transformation Officer. Jochen Profit, M.D., MPH, will join Dr. Barry as Chief Quality Advisor.


“We are thrilled to welcome two nationally renowned physician leaders to Pediatrix and Obstetrix,” said Mark Ordan, Chair of the Board and CEO. “Quality care is at the heart of everything that we do as a leading provider of care for women, babies and children. Drs. Barry and Profit’s enormous experience and expertise will help us continue to advance both clinical knowledge and practice for the entire field.”


As Chief Clinical Quality & Transformation Officer, Dr. Barry will be responsible for shaping the medical direction of the organization and ensuring the highest standards of patient care. This includes overseeing the work of the Pediatrix Center for Research, Education, Quality and Safety (CREQS), which participates in clinical research, education and continuous quality improvement and safety initiatives at the local and national level to improve outcomes, enhance the patient experience, improve provider satisfaction and reduce health care costs.


“At a time when medical knowledge continues to grow exponentially and technology is reshaping care, Dr. Barry’s proven track record as a strategist and innovator will be an incredible asset to our organization and our patients as we move forward,” said Ordan.


A neonatologist recognized for his contributions in neonatal critical care, artificial intelligence in medicine, patient safety and health care leadership, Dr. Barry’s work has focused on delivering measurable, durable improvement in complex health care systems. He has co-founded two national organizations: NeoMINDAI, a learning collaborative for neonatologists, data scientists and clinical informaticists interested in studying and evaluating the application of artificial intelligence in neonatal critical care and pediatric medicine, and the Clinical Leader’s Group of the American Academy of Pediatrics, which is a training, education and collaboration resource for medical and quality directors of neonatal intensive care units (NICUs) in the United States. Dr. Barry joins Pediatrix from the University of Colorado Health System, where he was the long-standing Medical Director of a level III NICU and chair of newborn governance across 14 hospitals, as well as a professor of pediatrics-neonatology at the University of Colorado Anschutz School of Medicine.


“I am honored to be joining Pediatrix,” said Dr. Barry. “While our organization is built on a foundation of incredible clinical excellence and unmatched scale, I believe our true strength lies in our collective intelligence. By combining our clinical heart and genuine curiosity with transformative strategy, we will ensure that evidence-based approaches are more accessible and effective across all our clinical sites.”


Dr. Profit is a noted health care researcher with more than 20 years of experience in pediatrics and neonatal-perinatal medicine. As Chief Quality Advisor, he will provide expert medical guidance to the company’s affiliated clinical leaders and CREQS. His research has primarily focused on the optimization of care delivery to pregnant people and sick newborns and included health system design, care culture and provider well-being, health equity and family-centered care. Dr. Profit serves as Chair and Co-Principal Investigator at the California Perinatal Quality Care Collaborative, Co-Chair and Co-Principal Investigator at the California Maternal Quality Care Collaborative and is the Wendy J. Tomlin-Hess Endowed Professor of Pediatrics at Stanford Medicine. He is a board member of the California Association of Neonatologists and has served in a variety of roles for the National Institutes of Health, the National Academies for Science, Engineering and Medicine, the Vermont Oxford Network and the American Academy of Pediatrics.


“Dr. Profit is widely recognized as among the foremost thought leaders in our field, and we are excited that he is bringing his talents to Pediatrix, where his unyielding focus on improving quality and patient safety will have a national impact,” said Ordan.


About Pediatrix Medical Group


Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260324172077/en/
For media inquiries or more information, please contact Pediatrix Communications at communications@pediatrix.com.


Original: Pediatrix Welcomes Two Nationally Renowned Physician Leaders

Pediatrix Medical Group Announces 47th Annual NEO: The Conference for NeonatologyFebruary 23, 2026 6:00 AM
Business Wire
Leading Educational Event Brings Together Neonatal-Perinatal Medicine Clinicians Dedicated to Improving Outcomes in Newborn Care


Pediatrix® Medical Group, Inc. (NYSE: MD), a leading provider of physician services, is proud to host the 47th annual NEO: The Conference for Neonatology, taking place Feb. 25-27 in Las Vegas. NEO brings together top neonatology experts to discuss current issues and new advances in neonatal medicine.


For over 45 years, Pediatrix has been a trusted leader in neonatology, caring for or providing diagnostics to approximately one-quarter of all newborn babies in the U.S.


The national rate of preterm birth remains at an all-time high at 10.4%, meaning about 380,000 babies – one in every ten – were born prematurely in 2024. The March of Dimes’ 2025 Report Card, released in November, revealed that the nation received a D+ grade for preterm births for the fourth year in a row.


“These results underscore the ongoing need for innovation in neonatal-perinatal medicine,” said Timothy Biela, M.D., a neonatologist at Pediatrix Neonatology of San Antonio and director of the NEO conference. “We take pride in leading research initiatives and offering continuing education not only for our own clinicians but also for all providers involved in this highly specialized field. Our goal is to enhance outcomes for our tiniest, highest-risk patients.”


Conference Overview


This year’s conference welcomes participants from across the globe to engage with leading experts who will share the latest research, innovations and pressing topics in neonatal-perinatal medicine. Attendees will gain insights from distinguished speakers and participate in interactive sessions designed to foster learning and collaboration among clinicians.


Session Highlights



Transforming Outcomes for Mothers and Babies



Neonatal Surgery and Nutrition: Bridging Innovation and Outcomes



Patent Ductus Arteriosus Management: Medical vs. Surgical



Ethical Considerations in Neonatal Care



From Oxygen to Artificial Intelligence: The Future of Neonatal Respiratory Care



Advancements in Neonatal Nutrition



Neonatal Point-of-Care Ultrasound (POCUS) Pre-Conference Workshop



These sessions are designed to address both clinical excellence and the evolving challenges faced by neonatal-perinatal teams. The Neonatal POCUS Pre-Conference Workshop offers hands-on experience with cutting-edge ultrasound techniques, supporting the advancement of bedside diagnostics and care.


Legends of Neonatology Hall of Fame


Pediatrix is honored to announce that Waldemar Carlo, M.D., will be inducted into the Legends of Neonatology Hall of Fame during the conference. Dr. Carlo is celebrated for his pioneering research in neonatal resuscitation, global health initiatives and commitment to improving neonatal outcomes worldwide. His work has influenced clinical protocols and shaped the next generation of neonatal care providers.


Accreditation


Participants attending the NEO conference will have the opportunity to earn accredited continuing education credits. The Pediatrix Center for Research, Education, Quality and Safety is accredited by:



The Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians, designating this live activity for a maximum of 20.00 AMA PRA Category 1 Credits™.



The American Nurses Credentialing Center’s Commission on Accreditation as a provider of nursing continuing professional development, designating this live activity for a maximum of 20.00 nursing contact hours.



About Pediatrix Medical Group


Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223873892/en/
For media inquiries, please contact:

communications@pediatrix.com


Original: Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology

Pediatrix Medical Group 2025 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 19, 2026February 9, 2026 6:45 AM
Business Wire
Pediatrix Medical Group, Inc. (NYSE: MD) will host an investor conference call and webcast on Thursday, February 19, 2026 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2025. A detailed press release will be issued the morning of February 19, 2026 before the securities markets open.


The investor conference call will be webcast and can be accessed at Pediatrix’s website, www.pediatrix.com/investors.


ABOUT PEDIATRIX MEDICAL GROUP


Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,400 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.


Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, its full year 2025 guidance, future impacts of legal, regulatory, political and macroeconomic developments and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the following: the impact of the Company’s practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the effects of economic conditions on the Company’s business; the effects of the Medicare Access and CHIP Reauthorization Act of 2015, the Affordable Care Act, the One Big Beautiful Bill Act and potential additional healthcare reform; the Company’s relationships with government-sponsored or funded healthcare programs and with managed care organizations and commercial health insurance payors; the impact of state budgetary constraints and uncertainty over the future of Medicaid; the impact of surprise billing legislation; the Company’s transition to a hybrid revenue cycle management model; the timing and contribution of future acquisitions or organic growth initiatives; the Company’s ability to comply with the terms of debt financing arrangements; and the effects of the Company’s transformation initiatives, including our renewed focus, and growth strategy for, the Company’s hospital-based and maternal fetal businesses.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260209580033/en/
Kasandra Rossi

Executive Vice President, Chief Financial Officer and Treasurer

954-692-7163

kasandra.rossi@pediatrix.com


Original: Pediatrix Medical Group 2025 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 19, 2026

Nothing to see here, just "SIDS." pic.twitter.com/FMVtXTfWEM— Died Suddenly (@DiedSuddenly_) May 8, 2025 $MD

NEWS: $MD Mednax Inc (MD) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Mednax Inc (NYSE: MD) Q3 2020 Earnings Call Nov 6, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: Mednax Inc (MD) Q3 2020 Earnings Call Transcript

In case you are interested MD - Mednax Inc (MD) Q3 2020 Earnings Call Transcript

My wife of over 30 years, Jacki died of Ovarian cancer, but this cancer could have been prevented if she was NOT bullied by her boss Carey Osborne at MEDNAX. I recently found a confession letter that she left me describing how Carey bullied her to the point that she was petrified of taking any time off for vacation or medical checkups/procedures. It seems that Carey always gave Jacki a hard time for any vacation, medical appointments for her or her elderly parents. MEDNAX is an awful Company to work for, totally incredible the lack of professionalism, human care, and empathy at MEDNAX. During her fight with cancer, she received a dismissal letter from MEDNAX after 20 years with the company with a registered letter. After 2 months from her death, she got almost 2 weeks pay of leftover sick time pay, but her boss would NOT let her take any time for medical needs!!! Stay away from MEDNAX.

they purchased southeast anas. in charlotte - over 100 doctors

Split on Friday...

MEDNAX Announces Acquisition of Neonatology Practice in Texas

ESOP 20% discount free trading shares...

MD is buying up medical practices nationwide. Dr.'s committed to 7 year employment agreements.

$4 billion market cap.

PE of 18 looks good

Welcome